EUVIMEDEUVIMED entdecken
Vergleichsstudie

Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon

Hashem B El-Serag, Hao Duong, Michelle Luster, Fasiha Kanwal, Deanna D Hill, Margaret Burroughs, Candido Hernandez, Barbara A Haber, Lois M Larsen, John F Marcinak, Lani R Wegrzyn, Xian Yu und 2 weitere

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18525 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Hashem B El-Serag und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: NIDDK NIH HHS, DAA PASS Hep C Consortium, Veterans Administration Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few studies have examined the risk of de novo hepatocellular carcinoma (HCC) among hepatitis C virus (HCV)–infected patients with cirrhosis who received interferon (IFN)‐free direct‐acting antiviral (DAA) therapy relative to patients who received IFN‐containing therapy or remained untreated.

Aims

To estimate the risk of de novo HCC with DAA treatment in cirrhotic HCV patients compared to no anti‐HCV treatment and those treated with IFN‐based therapy.

Methods

We identified patients with chronic HCV infection and compensated cirrhosis in the US Department of Veterans Affairs healthcare system treated with IFN (2005 to 2013) or DAAs (2013 to 2017). We compared the risk of de novo HCC for patients treated with DAAs, IFN‐containing regimens or no treatment after accounting for differences in demographics, alcohol and drug abuse, comorbidities, laboratory values, healthcare utilisation, prior HCV treatment and HCC surveillance.

Results

A total of 53,847 patients contributed to untreated time, 27,147 patients contributed to DAA‐treated time (15,641 contributed to both untreated and DAA‐treated times) and 6809 patients contributed to IFN‐treated time. HCC risk associated with DAA treatment was significantly lower than untreated [adjusted HR: 0.70 (95% CI: 0.65–0.74)]. The risk of HCC was not significantly different for patients treated with DAA compared with those treated with IFN [adjusted HR: 0.98 (95% CI: 0.87–1.10)].

Conclusions

The study shows a reduced risk of de novo HCC among patients with chronic HCV–related compensated cirrhosis who received DAA treatment compared to that of untreated patients. There were no differences in HCC risk between DAA‐treated and IFN‐treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCarcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisHepatitis C, ChronicInterferonsHumansMaleFemaleMiddle AgedUnited StatesAgedRisk Factors

Stichwörter der Autor:innen

cohort studycollider biasepidemiologyliver cancerviral hepatitis

Substanzen

Antiviral AgentsInterferons

Autor:innen und Institutionen

  • Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • AbbVie Inc., North Chicago, Illinois, USA.
  • Gilead Sciences, Inc., Foster City, California, USA.

ORCID-Profile: Jennifer R Kramer

Förderung

  • NIDDK NIH HHS
  • DAA PASS Hep C Consortium
  • Veterans Administration Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center
  • Cancer Prevention and Research Institute of Texas
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

El-Serag, H. B., Duong, H., Luster, M., Kanwal, F., Hill, D. D., Burroughs, M., Hernandez, C., Haber, B. A., Larsen, L. M., Marcinak, J. F., Wegrzyn, L. R., Yu, X., Richardson, P., & Kramer, J. R. (2025). Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18525

Vancouver

El-Serag HB, Duong H, Luster M, Kanwal F, Hill DD, Burroughs M, et al. Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18525

BibTeX
@article{ElSerag2025,
  author = {El-Serag, Hashem B and Duong, Hao and Luster, Michelle and Kanwal, Fasiha and Hill, Deanna D and Burroughs, Margaret and Hernandez, Candido and Haber, Barbara A and Larsen, Lois M and Marcinak, John F and Wegrzyn, Lani R and Yu, Xian and Richardson, Peter and Kramer, Jennifer R},
  title = {Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18525}
}
Kostenlos starten →